home / stock / drug:cc / drug:cc news

DRUG:CC News and Press, Bright Minds Biosciences Inc. From 10/05/22

Stock Information
Company Name: Bright Minds Biosciences Inc.
Stock Symbol: DRUG:CC
Market: CNQC
Website: brightmindsbio.com
Menu
DRUG:CC DRUG:CC Quote DRUG:CC Short DRUG:CC News DRUG:CC Articles DRUG:CC Message Board
Get DRUG:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
DRUG:CC - New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 –  A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effec...
DRUG:CC - Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“B...

DRUG:CC - Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

VANCOUVER, British Columbia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neur...

DRUG:CC - Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NAS...
DRUG:CC - Bright Minds Announces Pricing of Overnight Marketed Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (“ Bright Minds ” or the “ Company ”) (Nasdaq: DRUG) (CSE...

DRUG:CC - Bright Minds Announces Overnight Marketed Offering of Units

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (“ Bright ...

DRUG:CC - Bright Minds Biosciences Comments on Recent Trading Activity

VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsy...
DRUG:CC - Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neur...

DRUG:CC - Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) --  Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company&...

DRUG:CC - Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry, addiction, behavioral health, and pharmacology to guide Company’s development program...
Previous 10 Next 10